Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.34 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | GART | P22102 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
| ▸ | PRSS8 | Q16651 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650112 | 1.00 | LMNA (0.36) | LMNAMAPTCTSCPTPN1CTSB | |
| SCHEMBL6650104 | 1.00 | LMNA (0.36) | LMNAMAPTCTSCPTPN1CTSB | |
| SCHEMBL6633244 | 0.90 | CTSS (0.35) | LMNAPTPN1CTSSPTPN2 | |
| SCHEMBL6700654 | 0.90 | CTSS (0.35) | LMNAPTPN1CTSSPTPN2 | |
| SCHEMBL6700659 | 0.90 | CTSS (0.35) | LMNAPTPN1CTSSPTPN2 | |
| SCHEMBL6468744 | 0.89 | ALDH1A1 (0.39) | CTSCPTPN1CTSBCTSSCTSK | |
| Hydrochloric Acid SCHEMBL6465933 | 0.88 | ALDH1A1 (0.38) | CTSCPTPN1CTSBCTSSCTSK | |
| SCHEMBL5945973 | 0.88 | CTSS (0.34) | PTPN1CTSSPTPN2 | |
| SCHEMBL6464156 | 0.84 | CTSS (0.43) | LMNAMAPTCTSCCTSBCTSS | |
| SCHEMBL6062057 | 0.84 | CTSS (0.41) | MAPTCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | LMNA 1707/4885MAPT 2065/4885CTSC 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.